Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets
Increased Real-World Biomarker Test Utilization in Patients with Early-Stage Non-Small Cell Lung Cancer in the United States, 2011 to 2021
Real-World Study of Disease-Free Survival and Associated Patient Characteristics in Early-Stage Non–Small Cell Lung Cancer (NSCLC): A Retrospective Observational Study
Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC
CO154 Ramucirumab+Docetaxel Post Immune Checkpoint Inhibitors (ICIS) and Platinum-Based Chemotherapy (CHEMO) in Advanced or Metastatic Non-Small Cell Lung Cancer (ANSCLC): Learnings from the Treat-Lung Observational Study
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy
Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study
The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies
Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot
Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
